Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Ellard, Susan; Clemons, Mark; A. Gelmon, Karen; Norris, B.; F. Kennecke, Hagen; Chia, Stephen; I. Pritchard, Kathleen; Eisen, Andrea; Vandenberg, Ted; Taylor, Marianne; E. Sauerbrei, Eric; Mishaeli, Moshe; Huntsman, David; Walsh, Wendy; Olivo, Martin; McIntosh, L.; Seymour, Lesley

doi:10.1200/jco.2008.21.3033

Public

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Published in Journal of Clinical Oncology • Sep 20, 2009

Authors:

Susan Ellard

Mark Clemons

Karen A. Gelmon

Abstract

PURPOSE: To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore for possible biologic correlates of response. PATIENTS AND METHODS: Patients who...

Subject

Medicine

Internal medicine

Pneumonitis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!